Hydrochlorothiazide Reduces Cardiac Hypertrophy, Fibrosis and Rho-Kinase Activation in DOCA-Salt Induced Hypertension.
David Mondaca-RuffPatricio AraosCristián E YañezUlises F NovoaItalo G MoraMaría Paz OcaranzaJorge E JalilPublished in: Journal of cardiovascular pharmacology and therapeutics (2021)
HCTZ reduced pathologic LVH by controlling blood pressure, hypertrophy and myocardial fibrosis and by decreasing myocardial ROCK activation, expression of pro remodeling, pro fibrotic and pro oxidative genes. In hypertension, the observed effects of HCTZ on the myocardium might explain preventive outcomes of thiazides in hypertension, specifically on LVH regression and incident heart failure.
Keyphrases
- blood pressure
- heart failure
- hypertensive patients
- left ventricular
- anti inflammatory
- heart rate
- poor prognosis
- cardiovascular disease
- protein kinase
- systemic sclerosis
- tyrosine kinase
- type diabetes
- genome wide
- high glucose
- transcription factor
- blood glucose
- atrial fibrillation
- radiation therapy
- neoadjuvant chemotherapy
- cardiac resynchronization therapy
- smooth muscle
- drug induced
- acute heart failure